Introduction
Methods
Study Design
Statistical Analysis
Results
Baseline Characteristics
Variable | ≥ 65 years (N = 214) | < 65 years (N = 542) | p value |
---|---|---|---|
Age, years | 70.42 (4.35) | 54.25 (7.77) | < 0.001 |
Age, LY IGlar/SA IGlar, years (%) | 29.8/26.8 | 70.2/73.2 | 0.376 |
Sex, male, n (%) | 103 (48.1) | 275 (50.7) | 0.572 |
Race, n (%) | < 0.001 | ||
American Indian or Alaska Native | 2 (0.9) | 36 (6.6) | |
Asian | 14 (6.5) | 50 (9.2) | |
Black or African American | 9 (4.2) | 49 (9.0) | |
Multiple | 0 (0.0) | 3 (0.6) | |
White | 189 (88.3) | 404 (74.5) | |
Duration of diabetes, years | 14.42 (7.42) | 10.28 (6.17) | < 0.001 |
Weight (kg) | 85.95 (18.60) | 91.72 (19.80) | < 0.001 |
BMI (kg/m2) | 30.70 (5.35) | 32.37 (5.44) | < 0.001 |
Glycated hemoglobin (%) | 8.06 (0.99) | 8.43 (1.09) | < 0.001 |
Sulfonylurea use (yes), n (%) | 183 (85.5) | 447 (82.5) | 0.332 |
Time of basal insulin injection [AM/(PM or bedtime)], % | 47.2/52.8 | 50.6/49.4 | 0.420 |
Renal function status, n (%) | < 0.001 | ||
Normal GFR (> 90 mL/min/1.73 m2) | 70 (32.7) | 440 (81.2) | |
Mild reduction in GFR (60–89 mL/min/1.73 m2) | 112 (52.3) | 88 (16.2) | |
Moderate reduction in GFR (30–59 mL/min/1.73 m2) | 31 (14.5) | 13 (2.4) | |
Basal insulin (%), SA IGlar/none | 45.3/54.7 | 37.3/62.7 | 0.047 |
Efficacy
Safety
≥ 65 years | p value | < 65 years | p value | |||||||
---|---|---|---|---|---|---|---|---|---|---|
LY IGlar | SA IGlar | LY IGlar | SA IGlar | |||||||
N
| n (%) |
N
| n (%) |
N
| N (%) |
N
| N (%) | |||
Proportion of patients with detectable antibodies | ||||||||||
Baseline | 107 | 5 (4.7) | 97 | 1 (1.0) | 0.215 | 258 | 15 (5.8) | 268 | 12 (4.5) | 0.556 |
24-week endpoint (LOCF) | 107 | 3 (2.8) | 97 | 3 (3.1) | > 0.999 | 258 | 27 (10.5) | 268 | 19 (7.1) | 0.217 |
Overalla | 107 | 12 (11.2) | 97 | 4 (4.1) | 0.071 | 258 | 44 (17.1) | 268 | 36 (13.4) | 0.275 |
N
| Median (Q1, Q3) |
N
| Median (Q1, Q3) | p value |
N
| Median (Q1, Q3) |
N
| Median (Q1, Q3) | p value | |
---|---|---|---|---|---|---|---|---|---|---|
Endpoint median insulin antibody levels | ||||||||||
Baseline | 5 | 2.32 (0.44–2.97) | 1 | 0.96 (0.96–0.96) | > 0.999 | 15 | 0.71 (0.46–1.54) | 12 | 0.44 (0.34–0.78) | 0.251 |
24-week endpoint (LOCF) | 3 | 1.96 (1.11–5.66) | 3 | 0.45 (0.26–4.38) | 0.383 | 27 | 0.99 (0.38–5.14) | 19 | 0.65 (0.36–2.76) | 0.616 |
Adverse events, n (%) | ≥ 65 years | p value | < 65 years | p value | Treatment-by-age subgroup interaction | ||
---|---|---|---|---|---|---|---|
LY IGlar N = 112 | SA IGlar N = 102 | LY IGlar N = 264 | SA IGlar N = 278 | ||||
Patients with ≥ 1 TEAE | 63 (56.3) | 56 (54.9) | 0.843 | 133 (50.4) | 128 (46.0) | 0.313 | 0.714 |
Special topic assessmenta | 5 (4.5) | 7 (6.9) | 0.447 | 16 (6.1) | 20 (7.2) | 0.597 | 0.695 |
Injection site reactions | 4 (3.6) | 1 (1.0) | 0.211 | 9 (3.4) | 8 (2.9) | 0.723 | 0.337 |
Patients with ≥ 1 SAE | 8 (7.1) | 11 (10.8) | 0.351 | 7 (2.7) | 7 (2.5) | 0.922 | 0.487 |